SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit by Reale, Maria Lucia et al.
ORIGINAL RESEARCH
published: 19 August 2020
doi: 10.3389/fonc.2020.01722










Istituto Nazionale dei Tumori
(IRCCS), Italy
Jessica Desiree Menis,










This article was submitted to
Thoracic Oncology,
a section of the journal
Frontiers in Oncology
Received: 10 June 2020
Accepted: 31 July 2020
Published: 19 August 2020
Citation:
Reale ML, Bironzo P, Bertaglia V,
Palesandro E, Leone G, Tabbò F,
Bungaro M, Audisio M, Mariniello A,
Rapetti SG, Di Stefano RF, Artusio E,
Capelletto E, Sperone P, Boccuzzi A,
Calandri M, Perboni A, Malapelle U,
Passiglia F and Novello S (2020)
SARS-CoV-2 Infection in Cancer




SARS-CoV-2 Infection in Cancer
Patients: A Picture of an Italian
Onco-Covid Unit
Maria Lucia Reale 1, Paolo Bironzo 1*, Valentina Bertaglia 1, Erica Palesandro 1,
Gianmarco Leone 1, Fabrizio Tabbò 1, Maristella Bungaro 1, Marco Audisio 1,
Annapaola Mariniello 1, Simonetta G. Rapetti 1, Rosario F. Di Stefano 1, Elisa Artusio 1,
Enrica Capelletto 1, Paola Sperone 1, Adriana Boccuzzi 2, Marco Calandri 3,
Alberto Perboni 4, Umberto Malapelle 5, Francesco Passiglia 1 and Silvia Novello 1*
1Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy, 2 Emergency Medicine, San Luigi
Gonzaga Hospital, Turin, Italy, 3 Radiology Unit, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin,
Turin, Italy, 4 Pneumologia, San Luigi Gonzaga Hospital, Turin, Italy, 5Department of Public Health, University of Naples
Federico II, Naples, Italy
Background: The world, and Italy on the front lines, has experienced a major medical
emergency due to the novel coronavirus outbreak. Cancer patients are one of the
potentially most vulnerable cohorts of people, but data about their management are
still few.
Patients and Methods: In this monocentric retrospective study we included all
SARS-CoV-2 oncological patients accepted, between March 27th and April 19th
2020, at the Onco-COVID Unit at San Luigi Gonzaga Hospital, one of the few Italian
oncological-COVID wards. Data were obtained from medical records.
Results: Eighteen cancer patients with COVID-19 were included. The mean (±SD) age
of patients was 67 ± 14 years, 89% were men. Seven (39%) developed infection in
communities and 11 (61%) during hospitalization. Lung cancer was the most frequent
type of cancer (10, 56%). Seven patients (39%) were symptomatic for COVID-19 at
the time of diagnosis and symptoms began 2 (±2) days before. The most common
were shortness of breath and diarrhea. Fever was present in 5 patients (28%). Among
the 11 asymptomatic patients, 8 (73%) became symptomatic during the hospitalization
(mean time of symptoms onset 4 days ±4). Six patients (33%) were on active anti-tumor
treatment: 2 (33%) received anti-tumor therapy within 2 weeks before the infection
diagnosis and 2 (33%) continued oncological treatment after SARS-CoV-2 positivity.
Eight (44%) patients died within a mean of 12 days (±8) from the infection diagnosis.
Conclusions: Our series confirms the high mortality among cancer patients with
COVID-19. The presence of asymptomatic cases evidences that typical symptoms and
fever are not the only parameters to suspect the infection. The Onco-Covid unit suggests
the importance of a tailored and holistic approach, even in this difficult situation.
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INTRODUCTION
Over the past few months, the world has to face a major medical
emergency due to the novel coronavirus SARS-CoV-2 outbreak.
The high transmissibility rate and the rapid spread of the virus
have led the World Health Organization (WHO) to declare the
state of pandemic on March 11th 2020. More than 6 millions of
cases and 370,000 deaths from COVID-19 (the disease caused by
SARS-CoV-2) have been confirmed worldwide and Italy rapidly
became one of the most affected countries (1, 2).
Given the immunosuppression caused by the disease itself and
by antitumor treatments, cancer patients seem to be a vulnerable
population. National and international scientific societies have
drawn up specific recommendations in order to establish the
priorities in the oncological treatment and to mitigate the
negative effects of the pandemic on the management of cancer
patients (3–5).
Liang et al. reported a higher risk of developing the
infection, of critical events and of mortality rates for 18
Chinese cancer patients compared to the general population
(6). Another retrospective study conducted in three hospitals
in Wuhan confirmed high rates of severe events—exacerbated
by the administrations of anticancer treatment within 14 days
of infection—and of mortality (7). High rates of 30-day all-
cause mortality has also been confirmed by Cancer Consortium
(CCC19) data analysis (8). Myashita et al. stratifying 334
American cancer patients with COVID-19 infection by age
groups, detected a higher mortality in patients younger than 50
years (9).
More data are needed, however, to better understand the
risk and the best management of COVID-19 infection in cancer
patients. Issues concerning the prevalence of asymptomatic
patients, the time of symptoms onset, the best therapeutic
approach (antiviral and oncological), and the infection evolution
are still unsolved. Since the resolution of the current health crisis
looks as a long and not easy process, the collection of real-world
data is a valuable strategy. This retrospective study aims to collect
epidemiological, clinical, laboratory, and therapeutic data from
SARS-CoV-2 positive cancer patients hospitalized at the Onco-
Covid unit in San Luigi Gonzaga Hospital, Italy, one of the few
oncological wards for cancer patients with SARS-Cov-2 infection,
in order to provide a deeper insight into the clinical evolution of
infection in cancer patients, particularly in lung cancer patients.
METHODS
Study Population, Setting, and Data
Collection
The study was approved by the Ethics Committee of the AOUSan
Luigi Gonzaga, Orbassano (Turin). The requirement for specific
informed patient consent was waived due to the emergency
status, upon the approval of the Ethics Committee. However,
patients provided a general written informed consent for clinical
data collection at the time of hospitalization.
This retrospective study included all SARS-CoV-2 oncological
patients accepted at the Onco-Covid Unit at San Luigi Gonzaga
Hospital, Orbassano, between March 27th and April 19th 2020.
Clinical data was retrospectively retrieved from the medical
records, including demographic and clinical features, laboratory,
and radiological findings at presentation and during the
hospitalization. In particular, following internal hospital
protocol, a chest-X-ray or a chest ultrasound was executed at
baseline. In case of severe respiratory illness in patients with a
not poor prognosis, a computed tomography (CT) scan was also
obtained. The radiological assessment was monitored during the
hospitalization. However, all laboratory and radiologic tests were
performed at the discretion of the treating physicians, taking
into consideration patients’ general conditions and prognosis.
Patient data were censored at the time of data cutoff, which
coincides with the closing date of the ward and occurred on April
19th, 2020.
A confirmed case of Covid-19 was defined by a positive result
on a reverse-transcriptase–polymerase-chain-reaction (RT-PCR)
assay (VIASURE SARS-CoV-2 Real Time PCR Detection
Kit, targeting the SARS-CoV-2 S gene) performed on a
nasopharyngeal swab- derived specimen, following the WHO
criteria (10).
The ratio of arterial oxygen partial pressure (PaO2 in mmHg)
to fractional inspired oxygen (FiO2), defined as P/F, was used as
clinical indicator of hypoxemia.
Disease response (investigator-assessed) was defined
according to Response Evaluation Criteria In Solid Tumors
(RECIST) v. 1.1 criteria and to clinical evaluation.
The terms “best supportive care” were used to define care
given to patients with no more indications to active antitumor
treatment, aiming at improve the quality of life by preventing or
treating symptoms.
Statistical Analysis
Descriptive statistics were used to summarize the data;
results were reported as means and standard deviations
(SD). Categorical variables were summarized as counts and
percentages. Analysis was performed with IBM SPSS software.
RESULTS
Clinical Characteristics of the Patients
From March 27th to April 19th 2020, we identified 18 cancer
patients with confirmed SARS-CoV-2 positivity at the Onco-
Covid Unit.
The demographic and clinical characteristics are shown in
Table 1. The mean (±SD) age of the patients was 67 ± 14 years
(range 26–84); 16 (89%) were men. Twelve patients (66%) were
current or former smokers.
Chronic medical conditions, beside the oncological disease,
were present in 12 (67%) patients. Nine patients (50%) had
hypertension, 2 (11%) chronic obstructive pulmonary disease, 2
(11%) diabetes mellitus, and 1 (6%) ischemic cardiomyopathy.
Seven patients (39%) were in antihypertensive treatment, 8
(44%) in anticoagulant/antiplatelet therapy for primary or
secondary prevention, 2 (11%) in hypoglycemic therapy. Before
the diagnosis of infection, 4 patients (22%) received systemic
glucocorticoids and none of them was under oxygen therapy.
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TABLE 1 | Clinical characteristics of the patients at baseline+.
Clinical characteristics of the patients at baseline
Number of patients 18
Age (range) Mean 67 years ± 14 (26–84)
Sex—no. (%) Male: 16 (89)
Female: 2 (11)
Smoking habit—no. (%) Never: 1 (6)
Former: 6 (33)
Current: 6 (33)
Missing data: 5 (28)
BMI* Mean: 24 ± 4 (16–30)
Coexisting disorder—no. (%)
None 6 (33)
Chronic obstructive pulmonary disease 2 (11)
Diabetes mellitus 2 (11)
Hypertension 9 (50)






ECOG PS 0 2/18 (11)
ECOG PS 1 5/18 (28)
ECOG PS 2 9/18 (50)
ECOG PS 3 2/18 (11)
ECOG PS 4 0/18 (0)
Steroid treatment—no. (%) 4 (22)
Oxygen treatment—no. (%) 0 (0)
+Plus-minus values are means ± SD. Percentages may not total 100 because
of rounding.
*The body-mass index in the weight in kilograms divided by the square of the height in
meters. Data on body-mass index were missing for 5 patients.
Most patients presented with an Eastern Cooperative
Oncological Group (ECOG) Performance Status (PS) of 2 (9,
50%) and 1 (5, 28%).
As shown in Table 2, lung cancer was the most frequent type
of cancer (10, 56%), followed by blood/bone marrow cancer (3,
17%). Fourteen patients (78%) were diagnosed with stage IV, with
11 (61%) patients reporting a lung/pleura involvement. In most
of cases (13, 72%), the diagnosis of cancer had occurred in the
last 12 months.
Ten patients (56%) had already received a clinical indication
to home-based best supportive care before the infection; six
patients (33%) were, on the contrary, on active anti-tumor
treatment, a first line therapy in 4 (67%) cases. Two patients
(11%), with a new cancer diagnosis were potentially candidates
to medical treatment, but were still naïve at the time of infection.
The last anti-cancer therapy received by patients on treatment
was chemotherapy, immunotherapy or tyrosine kinase inhibitors
(TKIs) in 2 (33%), 3 (50%), and 1 (17%) patients, respectively.
Two patients (33%) received anti-tumor therapy within 3 weeks
before SARS-CoV-2 positivity and other two (33%) within 2
TABLE 2 | Cancer type and treatment history.
Cancer type and treatment history*





Blood/bone marrow 3/18 (17)
Brain (low grade) 1/18 (6)
Neuroendocrine cells (Paraganglioma) 1/18 (6)
Stage IV—no. (%) 14/18 (78)
Presence of lung/pleura disease—no. (%) 11/18 (61)
Time from oncological diagnosis to COVID-19 positivity—no. (%)
≥24 months 2/18 (11)
24–12 months 3/18 (17)
<12 months 13/18 (72)
Oncological indications—no. (%)
Active anti-tumor treatment 6/18 (33)
New diagnosis-active treatment candidates 2/18 (11)
Best supportive care 10/18 (56)
Line of therapy for patients in active anti-tumor treatment—no. (%)
Neoadjuvant 0/6 (0)
Adjuvant 0/6 (0)
I line 4/6 (67)
II line 1/6 (17)
III line and beyond 1/6 (17)
Type of therapy for patients in active anti-tumor treatment—no. (%)
Chemotherapy 2/6 (33)
Immunotherapy 3/6 (50)
Tyrosine Kinase Inhibitors 1/6 (17)
Time from last anticancer drug administration to
COVID-19 positivity for patients in active anti-tumor
treatment—no. (%)
3 weeks 2/6 (33)
2 weeks 1/6 (17)
1 week 1/6 (17)
Treatment ongoing (before and after the infection) 2/6 (33)
*Percentages may not total 100 because of rounding.
weeks. Two patients (33%) continued oncological treatment
(TKIs and chemotherapy) after the infection diagnosis.
Clinical, Laboratory, and Radiological
Features of the Patients at Baseline (First
SARS-CoV-2 Positivity)
The clinical, laboratory, and radiologic findings of the patients at
SARS-CoV-2 infection diagnosis were summarized in Table 3.
There were twomain clusters of patients: 7 (39%) patients who
developed infection in their communities and 11 (61%) during
the hospitalization (reasons of hospitalization are reported in
Supplementary Table 1.)
Seven patients (39%) were symptomatic for COVID-19
infection at the time of nasopharyngeal swab. The mean duration
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TABLE 3 | Clinical, laboratory, and radiological features of the patients at baseline
(First SARS-CoV-2 positivity).
Clinical, laboratory, and radiological features of the Patients at
Baseline (First SARS-CoV-2 Positivity)*
Source of infection—no. (%)
Community 7/18 (39)
Nosocomial transmission 11/18 (61)
Symptomatic patients—no. (%) 7/18 (39)
Mean duration of symptoms before diagnosis of
infection—days (range)
2 ± 2 (0–7)
Symptoms—no. (%)
Shortness of breath 2/18 (11)
Cough 1/18 (6)
Sputum production 1/18 (6)



















Distribution of laboratory findings no./total no. (%)
Lymphocyte count decrease 5/18 (28)
Platelet count decrease 4/18 (22)
C-reactive protein ≥5 mg/dl 14/18 (78)
Procalcitonin ≥0.5 ng/ml 1/18 (6)
Lactate dehydrogenase ≥240 U/liter 11/18 (61)
Chest radiography findings—no./total no. (%)
Bilateral infiltrates 5/12 (42)
Parenchymal consolidation 2/12 (17)
Clear 5/12 (42)
Abnormalities on chest ultrasound—no./total no. (%)
Negative 1/5 (20)
B-lines 3/5 (60)
Subpleural consolidations, irregular pleural line and
B-lines
1/5 (20)
Abnormalities on chest CT—no./total no. (%)
Bilateral ground-glass opacities 2/3 (67)
Parenchymal consolidation 1/3 (33)
Clear 0/3 (0)
*Plus-minus values are means± SD. Percentages may not total 100 because of rounding.
of symptoms before the diagnosis was 2 ± 2 days. The most
common were shortness of breath and diarrhea both occurring in
2 patients (11%). Among the 11 asymptomatic patients, 8 (72%)
became symptomatic during the hospitalization (mean time of
symptoms onset: 4 days ±4). Documented fever was present in
5 patients (28%).
Peripheral oxygen saturation (SpO2) overcame the 90% in 15
patients (83%) and was <85% in 3 patients (17%). P/F was <200
in 3 patients (17%), between 200 and 300 in 7 (39%) patients and
higher than 300 in 3 (17%).
C-reactive protein increase (≥5 mg/dl) was detected in 14
(78%) patients. High lactate dehydrogenase levels (≥240 U/l)
were present in 11 patients (61%), while lymphocytopenia
and thrombocytopenia in 5 and 4 (28 and 22%), respectively.
A procalcitonin increase (≥0.5 ng/ml) was detected only in
1 patient (6%).
A chest radiograph was obtained in 12 patients (67%).
The radiographs showed bilateral infiltrates and parenchymal
consolidation in 5 and 2 cases (42 and 17%), respectively. A
thoracic ultrasound was executed in 5 patients: no anomalies
in one case (20%), B-lines in 3 patients (60%), B-lines plus
sub pleural consolidations plus irregular pleural line in another
case (20%). In 5 patients (42%) no radiological anomalies were
evident. A computed tomography (CT) scan of the chest was
obtained in 3 patients (17%), with 2 scans showing newly-
appeared bilateral ground glass opacities in one case and
parenchymal consolidations in the other one.
Treatment, Clinical Evolution and
Outcomes
The trend of the P/F analyzed after 7 and 14 days (±2) after
the SARS-CoV-2 positivity is shown in Table 4: P/F was <300
in 3 (21%) and four (30%) patients at the two reported intervals,
respectively. Sixteen patients (89%) received oxygen therapy with
nasal cannula (1–4 L/min), Venturi mask (24–31% or 35–60%),
reservoir or non-invasive ventilation with continuous positive
airway pressure (CPAP), as reported in Figure 1. None of them
received endotracheal intubation or invasive ventilation.
Laboratory findings during the hospitalization are reported in
Table 4.
A second chest X-ray was performed after 14 days from the
diagnosis of infection in 7 patients (58%), showing a radiological
improvement in 2 (17%), deterioration in 3 (25%), and stability
in 2 (17%) patients. In one of the latter, affected by lung
cancer and treated with a combination of TKI and COVID-19
directed therapy, a CT scan was also performed, showing both
the persistence of inflammatory lung infiltrates and a tumor
partial response.
In absence of robust evidences therapeutic management was
based on local guidelines and daily multidisciplinary evaluations
involving oncologists together with pulmonologists, intensive
care, and infectious disease specialists. Seven (39%) patients were
prescribed hydroxychloroquine for up to 10 days and 4 (22%)
antiviral therapy with lopinavir/ritonavir or darunavir/ritonavir
for 7 consecutive days. Antibiotics and systemic glucocorticoids
treatment were administered to 15 (83%) and 14 patients (78%),
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TABLE 4 | Treatment, clinical evolution and outcomes*.
















Intravenous antibiotics 15/18 (83)
Systemic glucocorticoids 14/18 (78)
Distribution of laboratory findings n./total no. (%)
Lymphocyte count decrease 7/18 (39)
Platelet count decrease 6/18 (33)
C-reactive protein ≥5 mg/liter 12/18 (67)
Procalcitonin ≥0.5 ng/ml 1/18 (6)
Lactate dehydrogenase ≥240 U/liter 8/18 (44)
Control chest radiography findings—n./total no. (%)
Improvement 2/12 (17)
Unchanged appearance 2/12 (17)
Deterioration 3/12 (25)
Not executed 5/12 (42)
Mean length of hospital stay from hospitalization at
data cut-off—days (range)
30 ± 14 (0–53)
Mean length of hospital stay from COVID19
positivity at data cut-off—days (range)
16 ± 9 (0–37)
Nasal swab—n./total no. (%)
Negative 6/18 (33)
Positive 4/18 (22)
Not done 8/18 (44)
Complications no. (%)
Septic shock 1/18 (6)
Acute respiratory distress syndrome 3/18 (17)
Progression of disease 9/18 (50)
None 4/18 (22)
Clinical outcomes at data cutoff—no. (%)
Hospitalization 4/18 (22)
Admission to a mild intensive care COVID department 1/18 (6)
Discharge from hospital (active treatment) 1/18 (6)
Discharge from hospital (best supportive care) 4/18 (22)
Death 8/18 (44)
*Plus-minus values are means± SD. Percentages may not total 100 because of rounding.
respectively, and just 4 of them were in on steroid treatment
before the diagnosis of infection.
The most common complication was the progression of
oncological disease (9, 50%) followed by Acute Respiratory
Distress Syndrome (ARDS) (3, 17%) and septic shock (1, 6%).
Nasal and/or pharyngeal swabs tested for SARS-CoV-2 were
collected after 14 days from the first positivity in 10 (56%)
patients: 6 (33%) resulted negative (with a second confirmatory
test performed at 24 h from the previous negative one) and 4
(22%) persistently positive.
As of April 19th, 8 (44%) died with a mean of 12 days
(±8, range 0–24) from the diagnosis of COVID-19 infection to
death. Five (28%) patients have been discharged from the Onco-
Covid Unit but remained in the hospital, 4 (22%) have been
transferred to another low intensive care COVID department and
1 (6%) to a mild intensive care unit. Five patients (28%) have
been discharged from the hospital, 4 (22%) of them with the
indication to best supportive care and 1 (6%) to active antitumor
treatment. The mean length of hospitalization at data cut-off
was 30 days ±14 (0–53), while it resulted 16 ± 9 days (0–
37) when calculated from COVID 19 positivity (characteristics
and outcomes of individual patients included in the analysis are
reported in Supplementary Table 2).
DISCUSSION
This monocentric retrospective case series describes the 18
cancer patients, whose 10 (56%) affected by lung cancer,
who developed laboratory-confirmed COVID-19 infection and
have been hospitalized at the Onco-Covid Unit of San Luigi
Gonzaga Hospital, one of the few oncological wards dedicated
to cancer patients with SARS-Cov-2 infection, between March
27th and April 19th, 2020. In our series, 11 (61%) patients
developed infection during their hospitalization at our oncology
department. The internal transmission was probably due to a
patient’s contact with a caregiver subsequently known to have
been ill, only few days after the identification of the first case
in our Region. When the first evidence of infection occurred,
we performed screening test even in asymptomatic hospitalized
patients in order to provide a rapid isolation of any positive
case. Out of 24 hospitalized patients, 10 resulted positive for
SARS-CoV-2 infection. Thus, after the transfer of negative
patients to other wards, we created the Onco-Covid Unit.
From that moment we admitted only infected cancer patients
coming from the Emergency Department, where nasopharyngeal
swab was always performed before hospitalization. We also
empowered the use of personal protective equipment (PPE) such
as hand sanitizer, isolation gown, filtered masks, face shield
or goggles, and gloves. In their analysis, Zhang et al. reported
that 29% of patients had developed COVID-19 infection during
hospitalization (7). In a Chinese retrospective study among the
138 hospitalized patients included, 41% were presumed to have
been infected in hospital−5 of them coming from the oncology
department—and 29% were health care workers (11). These
data underline the importance of both control measures and
PPE adoption to slow down the infection risk. In our center,
we regularly perform a triage of all subjects before entering
the hospital with body temperature measure and questionnaire
about epidemiological status and clinical conditions. We also
forbid hospital access to caregivers, even after the first epidemic
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FIGURE 1 | Oxygen therapy for Individual Patients Included in the Case Series. As of April 19th, 2020, a total of 8 patients (44%) had died. Five patients (28%) had
been discharged from the hospital. Here we report the oxygen therapy received by each patient during the hospitalization. The number of each patient corresponds to
that reported in Supplementary Table 2 showing individual clinical characteristics and outcomes.
phase, although we acknowledge its heavy emotional impact on
hospitalized patients experiencing complete isolation. Caregivers’
visits are allowed in case of rapid clinical deterioration with the
proper use of PPE.
The screening testing executed in the oncology ward, provided
the opportunity to observe the clinical evolution of asymptomatic
SARS-CoV-2 infection in the oncological population. Indeed,
only seven 7 patients (39%) were symptomatic, a lower
percentage as compared to what has been previously reported (7).
The mean time to the onset of any infection-related symptoms
in asymptomatic population was 4 days, with 3 patients who
remained asymptomatic during the entire observation period.
To our knowledge, this is the first reported series describing
the evolution of infection of SARS-CoV-2 in asymptomatic
cancer patients.
In symptomatic patients, shortness of breath and diarrhea
were themost common presenting symptoms (11%), with amean
duration before the diagnosis of infection of 2 days (0–7 days).
Only 5 patients (28%) had fever and 3 (17%) patients showed
a <85% peripheral oxygen saturation at the time of infection
diagnosis. Altogether, these data suggest that such symptoms and
fever may not be the only useful parameters to suspect COVID-
19 in cancer patients. Lung cancer, as in other analyses, was the
most frequent type of cancer (56%) and most patients (78%)
were diagnosed with stage IV disease (6, 7). Furthermore, data
from the TERAVOLT registry suggests high mortality and low
admission to intensive care in patients with thoracic cancer (12).
The majority of patients had chronic illnesses
beside the oncological disease, most commonly
hypertension. C-reactive protein increase and high lactate
dehydrogenase levels were frequent laboratory alterations
at baseline.
Radiological patterns of COVID-19 lung disease
were extremely heterogeneous showing bilateral
infiltrates/parenchymal consolidations or a clear
appearance (42%).
Regarding antiviral interventions, 39% received off-
label hydroxychloroquine and 22% lopinavir/ritonavir (or
darunavir/ritonavir) following local guidelines subsequently
modified because of hydroxychloroquine suspension by
regulatory agencies (13, 14). We have insufficient information,
however, to report associated outcomes. The absence of patients
treated with immune suppressive drugs and with remdesivir,
despite their promising results, is due to the high rate of patients
with a poor performance status as well as to the treatment criteria
established by local guidelines (13, 15). Only one patient was
deemed, based on respiratory illness and oncological prognosis,
to these treatments but, fortunately, his clinical conditions
improved with the only combination of hydroxychloroquine
and darunavir/ritonavir. None of the patients was intubated,
reflecting the high rate of patients with a compromised status
and without active antitumor indications even before SARS-
CoV-2 infection. The choice not to intubate critical patients
was always based on a multidisciplinary discussion tailored
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on every single case, taking into consideration the patient’s
clinical condition and prognosis that, for most of them, was
unfortunately poor.
Systemic glucocorticoids were administered to 14 patients
(78%), mostly taking into account some promising results of
glucocorticoids in improving clinical outcomes in patients with
respiratory illness, even if data were still conflicting (16, 17).
More recently, however, the benefit of glucocorticoids has been
demonstrated in the preliminary report of the RECOVERY trial
in which the use of dexamethasone resulted in lower mortality
among those who were receiving either invasive mechanical
ventilation or oxygen (18).
To date, recent anticancer treatment appears to increase the
risk of severe events in case of Sars-Cov-2 infection, except for the
results of the UK Coronavirus Cancer Monitoring Project where
recent chemotherapy use in cancer patients before infection was
not significantly associated with increased mortality (6, 7, 19).
However, in our case series two cancer patients continued on
receiving anti-tumor treatment after having acquired COVID-19
infection during the hospitalization. One of them was a 26-year-
old man with a new diagnosis of acute promyelocytic leukemia
and the other one was a 46-year-old man with a new diagnosis
of EGFR (Epidermal Growth Factor Receptor) mutated non-
small cell lung cancer. In the first case the diagnosis of the most
curable subtype of acute myeloid leukemia that, however, can
have a substantial rate of mortality within the first week/month
and the young age, were the cornerstone for deciding to start the
specific hematological treatment even in the presence of SARS-
CoV-2 infection. The management of patient was based on a
daily collaborative work with hematologists. A bone marrow
aspirate performed at the end of April showed flow cytometric
remission. In the second case, as previously reported, after a
careful assessment of risks and benefits, the patient was treated
with a combination of osimertinib and COVID-19 directed
agents under a close clinical and laboratory monitoring achieving
a radiological partial response.
The most common complications in the whole study
population were tumor progression (50%), ARDS (17%) and
septic shock (6%). The case fatality rate of 44% in this series (to
date) is higher than already reported by other Authors (6, 7).
One reason might be ascribed to the high percentage of patients
already hospitalized because of a clinical deterioration (22%).
For this latter reason, clinical management might have been
less aggressive, as prognosis was deemed poor even before the
diagnosis of COVID-19. Moreover, our case fatality rate may
be underestimated, considering that 4 patients were discharged
with the indication to best supportive care at the time data
were censored.
Globally, our series confirms a higher mortality rate in cancer
patients with COVID-19 when compared to regional mortality
rate (8% as of June 1st), even if a direct comparison with
the general population was not performed (20). Importantly,
however, 50% of patients in our series had an ECOG
performance status of 2 at the time of hospital admission,
only partially representing a typical cancer patients cohort.
Moderate or poor ECOG performance status is a well-known
poor prognostic factor, further explaining the high mortality
rate observed.
Our study has many important limitations, especially
its retrospective nature. For this reason, some cases had
either missing laboratory data or radiological evaluations
or both (all exams were performed at the discretion of
the treating physicians). Second, the sample size is small,
limiting its generalizability. Third, as we focused on the
entire population of cancer patients, sample is highly
heterogeneous regarding tumor type, stage of disease,
performance status, treatments. Finally, 5 patients (28%)
remained in hospitals at the time of data censoring on April
19th, 2020; as a result, outcomes for those patients were
not known.
To our knowledge, this is the first report of a pure Onco-
Covid reality. Although our study reinforces the fragility
of oncological patients during this emergency, cancer is
not a homogeneous disease and potential differences in
therapeutic options and prognosis are substantial, even
in advanced stage. For this reason, oncologists have to
be involved in the management of all cancer patients
affected by COVID-19 for a shared decision-making process
aimed at tailoring decisions on every patient reducing any
risks of under- or over-treatment. The Onco-Covid Unit
has represented an example, although perfectible, of this
tailored and holistic approach, even in a challenging situation
like SARS-CoV-2 pandemic.
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